• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[A multicenter study of defibrotide in the prevention of deep venous thrombosis. Final results].

作者信息

Gerosa C, Calvani A B, Cornelli U, Dina F, Ferrari P A, Ratti G, Nazzari M

出版信息

Minerva Chir. 1989 May 31;44(10):1507-16.

PMID:2671797
Abstract

In an open multicenter comparative study aimed at the evaluation of the efficacy of defibrotide and calcium heparin in the prophylaxis of postoperative deep vein thrombosis (DVT) and pulmonary embolism (PE) an evaluation has been made on 4810 patients. 2810 patients received defibrotide (800 mg/die: 400 mg b.i.d. or 200 mg q.i.d. by IV route); 2000 patients received calcium heparin (500 IU b.i.d. or t.i.d. by SC route) till the 7th post-operative day. The diagnosis of DVT or pulmonary embolism (PE) was made according to clinical routine criteria. The incidence of DVT has been 33/2810 (1.17%) in the defibrotide group and 47/2000 (2.35%) in the heparin group (chi 2 p = 0.002), while the cases of suspected or ascertained PE have been respectively 15/2810 (0.53%) and 23/2000 (1.15%) (p = 0.025). The post-operative course was totally normal in both groups; no significant adverse reactions were noticed. The obtained results suggest the effectiveness of defibrotide as an alternative to heparin in the prevention of post-operative DVT.

摘要

相似文献

1
[A multicenter study of defibrotide in the prevention of deep venous thrombosis. Final results].
Minerva Chir. 1989 May 31;44(10):1507-16.
2
[Defibrotide in the prevention of deep venous thrombosis in general surgery. Preliminary results of a multicenter study].[去纤苷预防普通外科深静脉血栓形成。一项多中心研究的初步结果]
Minerva Med. 1988 Jul;79(7):551-61.
3
[Comparative study of defibrotide and calcium heparin in the prevention of postoperative deep venous thrombosis. A randomized multicenter study].[去纤苷与肝素钙预防术后深静脉血栓形成的对比研究。一项随机多中心研究]
Minerva Med. 1988 Sep;79(9):783-90.
4
[Defibrotide in the prevention of deep venous thrombosis in gynecologic surgery. A controlled study versus calcium heparin in 120 patients].
Minerva Ginecol. 1990 Mar;42(3):79-85.
5
[The postoperative prevention of deep venous thrombosis and pulmonary embolism with defibrotide versus heparin-calcium: a randomized clinical multicenter study of 1296 patients undergoing major abdominal surgery].去纤苷与肝素钙用于腹部大手术后深静脉血栓形成和肺栓塞的术后预防:一项纳入1296例接受腹部大手术患者的随机临床多中心研究
Ann Ital Chir. 1992 Jan-Feb;63(1):83-8.
6
[Prevention of deep venous thrombosis with defibrotide in chest surgery. Controlled multicenter study versus heparin].[去纤苷预防胸部手术中深静脉血栓形成。与肝素对照的多中心研究]
Minerva Med. 1987 Jun 15;78(11):745-50.
7
[Defibrotide and heparin in the prevention of deep venous thromboses. A controlled study].[去纤苷与肝素预防深静脉血栓形成的对照研究]
Minerva Chir. 1990 Aug;45(15-16):1029-33.
8
Prevention of deep venous thrombosis in orthopedic surgery: effects of defibrotide.骨科手术中深静脉血栓的预防:去纤苷的作用
Clin Ther. 1988;10(4):350-7.
9
[Prevention of thromboembolism in patients operated on for hip prosthesis].
Minerva Med. 1988 May;79(5):367-72.
10
[The prevention of deep venous thromboses after radical or modified mastectomy interventions].[根治性或改良乳房切除术后深静脉血栓形成的预防]
Minerva Chir. 1990 Nov;45(21-22):1389-92.

引用本文的文献

1
Defibrotide Therapy for SARS-CoV-2 ARDS.地塞米松联合肝素与单独使用肝素治疗 COVID-19 相关急性呼吸窘迫综合征的随机对照临床试验
Chest. 2022 Aug;162(2):346-355. doi: 10.1016/j.chest.2022.03.046. Epub 2022 Apr 9.
2
The use of defibrotide in blood and marrow transplantation.在血液和骨髓移植中使用地夫可特。
Blood Adv. 2018 Jun 26;2(12):1495-1509. doi: 10.1182/bloodadvances.2017008375.
3
Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.去纤苷。对其药效学和药代动力学特性以及在血管疾病中的治疗用途的综述。
Drugs. 1993 Feb;45(2):259-94. doi: 10.2165/00003495-199345020-00007.